Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition

[Image: see text] Symmetric, dimeric daclatasvir (BMS-790052) is the clinical lead for a class of picomolar inhibitors of HCV replication. While specific, resistance-bearing mutations at positions 31 and 93 of domain I strongly suggest the viral NS5A as target, structural mechanism(s) for the drugs’...

Descripción completa

Detalles Bibliográficos
Autores principales: Nettles, James H., Stanton, Richard A., Broyde, Joshua, Amblard, Franck, Zhang, Hongwang, Zhou, Longhu, Shi, Junxing, McBrayer, Tamara R., Whitaker, Tony, Coats, Steven J., Kohler, James J., Schinazi, Raymond F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266333/
https://www.ncbi.nlm.nih.gov/pubmed/25365735
http://dx.doi.org/10.1021/jm501291c

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266333/
https://www.ncbi.nlm.nih.gov/pubmed/25365735
http://dx.doi.org/10.1021/jm501291c

Ejemplares similares